Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Bronchitis : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
References

Related Articles
Asthma

Chronic Obstructive Pulmonary Disease and Emphysema

Pediatrics, Bronchiolitis

Pediatrics, Croup or Laryngotracheobronchitis

Pediatrics, Pertussis

Pneumonia, Bacterial

Pneumonia, Mycoplasma




Patient Education
Asthma Center

Asthma Overview

Asthma Causes

Asthma Symptoms

Asthma Treatment




Author: Samuel Ong, MD, Visiting Assistant Professor, Department of Emergency Medicine, University of California at Los Angeles Medical Center-Olive View

Editors: David FM Brown, MD, Assistant Professor, Department of Medicine, Division of Emergency Medicine, Harvard Medical School; Associate-Chief, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Paul Blackburn, DO, FACOEP, FACEP, Program Director, Department of Emergency Medicine, Maricopa Medical Center; Assistant Professor, Department of Surgery, University of Arizona; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School

Author and Editor Disclosure

Synonyms and related keywords: tracheobronchitis, chronic obstructive lung disease, COLD, obstructive airway disease, OAD, chronic obstructive pulmonary disease, COPD, respiratory tract infection, asthma, viral respiratory tract infection, bacterial respiratory tract infection, chronic bronchitis, CB, acute bronchitis, cough, viral infection, adenovirus, influenza, parainfluenza, respiratory syncytial virus, RSV
 
rhinovirus, coxsackievirus, herpes simplex virus, HSV, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma species, air pollution, air pollutants, smoking, second-hand smoke, allergies, chronic aspiration, gastroesophageal reflux, GER, fungal infection

Background

Acute bronchitis refers simply to inflammation of the tracheobronchial tree. The cause is usually infectious, but allergens and irritants can produce a similar clinical picture. Bronchitis typically occurs in the setting of an upper respiratory illness; thus, it is observed more frequently in the winter months. Asthma can be mistakenly diagnosed as acute bronchitis if the patient has no prior history of asthma. In one study, one third of patients who had been determined to have recurrent bouts of acute bronchitis were eventually identified as having asthma.

Chronic bronchitis and acute exacerbations of chronic bronchitis are discussed in the eMedicine article Chronic Obstructive Pulmonary Disease and Emphysema.

Pathophysiology

Although bronchitis refers to inflammation of the trachea and bronchi, other segments of the respiratory tract may also be involved because acute bronchitis usually occurs in relation to the common cold or other respiratory illness.

Frequency

United States

According to the National Center for Health Statistics, more than 12 million cases of acute bronchitis occurred in 1994, a number roughly equal to 5% of the US population.1 In comparison, 91 million cases of influenza, 66 million cases of the common cold, and 31 million cases of other acute upper respiratory infections occurred during that same year.

International

Acute bronchitis is common throughout the world and is one of the top 5 reasons for seeking health care in countries that track such data.

Mortality/Morbidity

Bronchitis is nearly always self-limited in the otherwise healthy individual, although it frequently results in absenteeism from work and school. Severe cases occasionally produce deterioration in those with significant underlying cardiopulmonary disease or other comorbid conditions.

Sex

Although bronchitis seems to be diagnosed in women more frequently than in men, little difference is observed.

Age

Although found in all age groups, bronchitis is diagnosed most frequently in children younger than 5 years. In 1994, bronchitis was diagnosed in more than 11 of every 100 children younger than 5 years.1 This compared with only 4 of every 100 individuals in every other age group.



History

  • A purulent cough is generally the defining presentation for acute bronchitis.
  • The following symptoms may also be present:
    • Fever
    • Malaise
    • Rhinorrhea or nasal congestion
    • Sore throat
    • Wheezing
    • Dyspnea
    • Chest pain
    • Myalgias or arthralgias
  • Occupational history may be important in determining whether irritants play a role.

Physical

  • No uniform definition describes acute bronchitis. The physical examination findings may include rhonchi or wheezes; in most cases, the examination findings are unremarkable.
  • Occasionally, findings may suggest a particular etiology.

Causes

  • Influenza, parainfluenza, adenovirus, rhinovirus, and numerous other viruses have been implicated.
  • M pneumoniae and Chlamydia pneumoniae have also been implicated, but the role of other bacterial pathogens remains difficult to validate given the difficulties associated with collecting adequate sputum samples and the problem of asymptomatic carriage of putative pathogens such as Streptococcus pneumoniae and Haemophilus influenzae.
  • Bordetella pertussis should be considered in children who are incompletely vaccinated; however, studies increasingly report this bacterium as the causative agent in adults as well.2



Asthma
Chronic Obstructive Pulmonary Disease and Emphysema
Pediatrics, Bronchiolitis
Pediatrics, Croup or Laryngotracheobronchitis
Pediatrics, Pertussis
Pneumonia, Bacterial
Pneumonia, Mycoplasma

Other Problems to be Considered

Acute sinusitis
Aspiration
Bacterial tracheitis
Bronchiectasis
Cystic fibrosis
Influenza
Reactive airway disease
Retained foreign body



Imaging Studies

  • Chest radiography
    • Chest radiography may be necessary to exclude pneumonia, particularly when abnormalities in either the vital signs or pulse oximetry readings are observed.
    • Lungs appear normal in uncomplicated cases.



Emergency Department Care

Care for acute bronchitis is primarily supportive and should ensure that the patient is adequately oxygenating.



Therapy is generally symptomatic and includes use of analgesics, antipyretics, antitussives, and expectorants. Among otherwise healthy individuals, antibiotics have not demonstrated consistent benefit in the symptomatology or natural history of acute bronchitis.3, 4 Nonetheless, surveys from Europe, Australia, and the United States show that 80% of patients with acute bronchitis receive antibiotics. Antibiotic overuse contributes to the emergence of drug-resistant organisms. Cognizant of this, the Centers for Disease Control and Prevention (CDC) recently collaborated with numerous medical societies to publish a series of articles on the judicious use of antibiotics for several common conditions, including bronchitis, and have recommended against routine antibiotic use in uncomplicated bronchitis.

Patients are up to 4 times more likely to expect antibiotics for the diagnosis of bronchitis than for a chest cold. Therefore, limiting use of the diagnosis bronchitis may make reduction of antibiotic use more acceptable to patients.

Reviews have also noted that antibiotic use in smokers without chronic obstructive pulmonary disease is no more effective than in nonsmokers.5

Several studies have shown conflicting results on the use of zinc as an adjunct treatment against influenza A.6 Some recent studies have shown favorable results; however, participants complained of a bad taste and significant nausea. Broader use of zinc cannot be recommended at this time.

Drug Category: Antibiotics

Studies have focused on healthy individuals (excluding people with asthma) or patients with chronic obstructive pulmonary disease. Antibiotics may offer a small beneficial effect in patients with chronic obstructive pulmonary disease. Therefore, extending antibiotic therapy to people with asthma and other patients with limited cardiopulmonary reserve may be reasonable. If an antibiotic is to be used, a macrolide is a reasonable first choice because the macrolides are active against mycoplasmal and chlamydial organisms and B pertussis.

Drug NameErythromycin (EES, E-Mycin, Ery-Tab)
DescriptionUsed for prophylaxis in patients with penicillin allergy who are undergoing dental, PO, or respiratory tract procedures. Inhibits RNA-dependent protein synthesis, possibly by stimulating dissociation of peptidyl tRNA from ribosomes, resulting in arrest of bacterial replication.
Adult Dose250-500 mg PO qid or 333 mg PO tid
Pediatric Dose30-50 mg/kg/d PO divided qid
ContraindicationsDocumented hypersensitivity; hepatic impairment
InteractionsCoadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin or simvastatin increases risk of rhabdomyolysis
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsCaution in liver disease; estolate formulation may cause cholestatic jaundice; adverse GI effects are common (administer doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur

Drug NameClarithromycin (Biaxin)
DescriptionReversibly binds to P site of 50S ribosomal subunit of susceptible organisms and may inhibit RNA-dependent protein synthesis by stimulating dissociation of peptidyl tRNA from ribosomes, inhibiting bacterial growth.
Adult Dose250-500 mg PO bid
Pediatric Dose7.5 mg/kg PO bid
ContraindicationsDocumented hypersensitivity; concurrent pimozide
InteractionsToxicity increases with coadministration of fluconazole or pimozide; effects decrease and GI adverse effects may increase with coadministration of rifabutin or rifampin; may increase toxicity of anticoagulants, cyclosporine, tacrolimus, digoxin, omeprazole, carbamazepine, ergot alkaloids, triazolam, and HMG CoA–reductase inhibitors
Plasma levels of certain benzodiazepines may increase, prolonging CNS depression; arrhythmias and increase in QTc intervals occur with disopyramide; coadministration with omeprazole may increase plasma levels of both agents
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCoadministration with ranitidine or bismuth citrate not recommended if CrCl <25 mL/min; administer half dose or increase dosing interval if CrCl <30 mL/min; diarrhea may be sign of pseudomembranous colitis; superinfections may occur with prolonged or repeated antibiotic therapies

Drug NameAzithromycin (Zithromax)
DescriptionUsed to treat mild-to-moderate infections caused by susceptible strains of microorganisms; indicated for chlamydial and gonorrheal infections of genital tract.
Adult DoseDay 1: 500 mg PO
Days 2-5: 250 mg PO
Pediatric Dose12 mg/kg PO qd; not to exceed 500 mg/dose
ContraindicationsDocumented hypersensitivity; hepatic impairment; concurrent pimozide
InteractionsMay increase toxicity of theophylline, warfarin, and digoxin; effects reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsSite reactions can occur with IV route; bacterial or fungal overgrowth may result with prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in hospitalized, geriatric, or debilitated patients

Drug NameCefditoren pivoxil (Spectracef)
DescriptionSemisynthetic cephalosporin administered as prodrug. Hydrolyzed by esterases during absorption and distributed in circulating blood as active cefditoren.
Bactericidal activity results from inhibition of cell wall synthesis via affinity for penicillin-binding proteins.
No dose adjustment necessary for mild renal impairment (CrCl 50-80 mgL/min/1.73 m2) or mild-to-moderate hepatic impairment.
Indicated for the treatment of acute exacerbation of chronic bronchitis caused by susceptible strains of Streptococcus pyogenes.
Adult Dose400 mg PO with meals bid for 10 d
Moderate renal impairment (CrCl 30-49 mL/min/1.73 m2): Not to exceed 200 mg PO bid
Severe renal impairment (CrCl <30 mL/min/1.73 m2): 200 mg PO qd
Pediatric Dose<12 years: Not established
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity to drug, penicillin, related compounds, or milk protein sodium caseinate; carnitine deficiency or inborn errors of metabolism that may result in clinically significant carnitine deficiency
InteractionsAbsorption reduced with H2 receptor antagonists and antacids of magnesium and aluminum hydroxides; probenecid may increase plasma concentrations of cefditoren
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsMay cause diarrhea, nausea, and vaginal moniliasis (yeast infection); pseudomembranous colitis may occur; clinical manifestations of carnitine deficiency may occur with prolonged use; prolonged use may result in emergence and overgrowth of resistant organisms; caution in breastfeeding

Drug NameTetracycline (Sumycin)
DescriptionFor susceptible bacterial infections of both gram-positive and gram-negative organisms as well as infections caused by mycoplasmal, chlamydial, or rickettsial organisms. Inhibits bacterial protein synthesis by binding with 30S and, possibly, 50S ribosomal subunit(s). Provides coverage for mycoplasmal, chlamydial, and B pertussis organisms, but less effective than erythromycin.
Adult Dose50-500 mg PO qid
Pediatric Dose<8 years: Not recommended
>8 years: 10-20 mg/lb (25-50 mg/kg) PO divided qid
ContraindicationsDocumented hypersensitivity; severe hepatic dysfunction
InteractionsBioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of PO contraceptives, causing breakthrough bleeding and increased risk of pregnancy; can increase hypoprothrombinemic effects of anticoagulants
PregnancyD - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
PrecautionsPhotosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; use during tooth development (ie, last half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines

Drug NameDoxycycline (Bio-Tab, Doryx, Vibramycin)
DescriptionProvides coverage for mycoplasmal and chlamydial organisms but not active against B pertussis; inhibits protein synthesis and bacterial growth by binding with 30S and, possibly, 50S ribosomal subunits of susceptible bacteria.
Adult Dose100 mg PO bid
Pediatric Dose<8 years: Not recommended
>8 years: 2-5 mg/kg/d PO qd or divided q12h; not to exceed 200 mg/d
ContraindicationsDocumented hypersensitivity; severe hepatic dysfunction
InteractionsBioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can increase hypoprothrombinemic effects of anticoagulants; can decrease effects of PO contraceptives, causing breakthrough bleeding and increased risk of pregnancy
PregnancyD - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
PrecautionsPhotosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; use during tooth development (ie, last half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines

Drug NameTrimethoprim-sulfamethoxazole (Bactrim)
DescriptionInhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid, inhibiting bacterial growth. Antibacterial activity of TMP-SMZ includes common urinary tract pathogens except Pseudomonas aeruginosa. Like tetracycline, has in vitro activity against B pertussis; not useful in mycoplasmal infections.
Adult Dose160 mg TMP/800 mg SMZ PO q12h for 10-14 d
Pediatric Dose<2 months: Contraindicated
>2 months: 15-20 mg/kg/d (TMP) PO divided tid/qid for 14 d
ContraindicationsDocumented hypersensitivity; megaloblastic anemia due to folate deficiency; age <2 mo
InteractionsMay increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenic purpura in elderly people; may increase phenytoin levels; may potentiate effects of methotrexate in bone marrow depression; may increase hypoglycemic response to sulfonylureas; may increase levels of zidovudine
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDiscontinue at first appearance of rash or sign of adverse reaction; obtain CBC counts frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, administer 5-15 mg/d leucovorin); caution in folate deficiency (eg, chronic alcoholism, elderly persons, those receiving anticonvulsant therapy, those with malabsorption syndrome); hemolysis may occur in G-6-PD deficiency; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); administer fluids to prevent crystalluria and stone formation

Drug Category: Analgesics/antipyretics

These agents are used to control fever as well as myalgias and arthralgias.

Drug NameIbuprofen (Ibuprin, Advil, Motrin)
DescriptionUsually DOC for treatment of mild to moderate pain if no contraindications are recognized. Inhibits inflammatory reactions and pain, probably by decreasing activity of enzyme cyclooxygenase, which results in inhibition of prostaglandin synthesis.
Adult Dose400-800 mg PO q4-6h
Pediatric Dose10 mg/kg PO q6-8h
ContraindicationsDocumented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding
InteractionsCoadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase risk of methotrexate toxicity; may increase phenytoin levels
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
PrecautionsCaution in CHF, hypertension, and decreased renal or hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy, monitor PT closely and instruct patients to watch for signs of bleeding

Drug NameAcetaminophen (Tylenol, Panadol, Aspirin-free Anacin)
DescriptionDOC for treatment of pain in those with documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or taking PO anticoagulants
Adult Dose625-1000 mg PO q4h; not to exceed 4 g/d
Pediatric Dose<12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d
>12 years: 325-650 mg PO q4h; not to exceed 5 doses in 24 h
ContraindicationsDocumented hypersensitivity; G-6-PD deficiency
InteractionsRifampin can reduce analgesic effects; coadministration with barbiturates, carbamazepine, hydantoins, or isoniazid may increase hepatotoxicity
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsHepatotoxicity possible in chronic alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate serious illness; acetaminophen is contained in many OTC products and combined use with these products may result in cumulative acetaminophen doses exceeding recommended maximum dose

Drug Category: Antitussives and expectorants

Little data on the efficacy of expectorants outside the test tube are available. The prototype antitussive, codeine, has been used successfully in some chronic cough and induced cough models;7 however, little clinical data on upper respiratory infections are available. Existing data indicate that codeine is slightly better or equal in efficacy to guaifenesin, dextromethorphan, or even placebo.

Drug NameGuaifenesin and codeine (Robitussin A-C, Guiatuss AC, Mytussin AC)
DescriptionTreats minor cough resulting from bronchial and throat irritation.
Adult Dose5-10 mL PO q4-8h; not to exceed 60 mL/d
Pediatric Dose1-1.5 mg/kg/d codeine PO divided qid
ContraindicationsDocumented hypersensitivity
InteractionsIncreases toxicity of CNS depressant drugs
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsDo not administer for productive cough or persistent chronic cough from emphysema; caution in renal impairment

Drug NameGuaifenesin with dextromethorphan (Humibid DM, Mytussin, Robitussin DM)
DescriptionTreats minor cough resulting from bronchial and throat irritation.
Adult Dose10 mL PO q4h
Pediatric Dose<2 years: Not recommended
2-6 years: 2.5 mL PO q4h
6-12 years: 5 mL PO q4h
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDo not use to treat productive cough or persistent chronic cough resulting from emphysema

Drug Category: Bronchodilators

Studies have shown that bronchodilators are advantageous and may even be superior to antibiotics for bronchitis symptoms. However, patient numbers in trials are disappointingly few given how commonly acute bronchitis is diagnosed.

Drug NameAlbuterol sulfate (Proventil, Ventolin)
DescriptionBeta-agonist used in treatment of bronchospasm refractory to epinephrine. Relaxes bronchial smooth muscle by action on beta2-receptors and shows little effect on cardiac muscle contractility.
Adult Dose2 puffs q4-6h or 2-4 mg PO tid/qid
Pediatric Dose0.1-2 mg/kg PO tid
ContraindicationsDocumented hypersensitivity
InteractionsBeta-adrenergic blockers antagonize effects; inhaled ipratropium may increase duration of bronchodilatation by albuterol; cardiovascular effects may increase with MAOIs, inhaled anesthetics, tricyclic antidepressants, or sympathomimetic agents
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in hyperthyroidism, diabetes mellitus, and cardiovascular disorders

Drug Category: Antiviral agents

Influenza vaccinations offer greater protection for the appropriate populations because they offer coverage for influenza A and B. Amantadine and rimantadine have been demonstrated to be useful during epidemics of influenza A. Zanamivir and oseltamivir are the neuraminidase inhibitors that are now preferred for chemoprophylaxis during outbreaks of influenza A and B, although data from institutional outbreaks are limited.

Drug NameOseltamivir (Tamiflu)
DescriptionInhibits neuraminidase, which is a glycoprotein on the surface of influenza virus that destroys an infected cell's receptor for viral hemagglutinin. By inhibiting viral neuraminidase, decreases release of viruses from infected cells and thus viral spread. Effective to treat influenza A or B. Start within 40 h of symptom onset. Available as cap and PO susp.
Adult DoseAcute illness: 75 mg PO bid for 5 d
Prophylaxis: 75 mg PO qd for 10 d
Pediatric DoseAcute illness:
<1 year: Not indicated
>1 year:
<15 kg: 30 mg PO bid for 5 d
>15-23 kg: 45 mg PO bid for 5 d
>23-40 kg: 60 mg PO bid for 5 d
>40 kg: Administer as in adults
Prophylaxis:
<1 year: Not established
>1 year:
<15 kg: 30 mg PO qd for 10 d
>15-23 kg: 45 mg PO qd for 10 d
24-40 kg: 60 mg PO qd for 10 d
>40 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in renal impairment, chronic cardiac or respiratory disease, and breastfeeding; do not use in children <1 y (preclinical trials have demonstrated death in young animals, possibly related to immature blood-brain barriers)

Drug NameZanamivir (Relenza)
DescriptionInhibitor of neuraminidase, which is a glycoprotein on the surface of the influenza virus that destroys the infected cell's receptor for viral hemagglutinin. By inhibiting viral neuraminidase, release of viruses from infected cells and viral spread are decreased. Effective against both influenza A and B. To be inhaled through Diskhaler PO inhalation device. Circular foil discs containing 5-mg blisters of drug are inserted into supplied inhalation device.
Adult DoseTreatment: 10 mg (2 inhalations, 5 mg/inhalation) inhaled PO q12h for 5 d; initiate within 2 d of symptom onset
Prophylaxis: 10 mg (2 inhalations, 5 mg/inhalation) inhaled PO qd for 10 d; initiate within 36 h of exposure
Pediatric DoseTreatment:
<7 years: Not established
>7 years: Administer as in adults
Prophylaxis:
<5 years: Not established
>5 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; obstructive airway disease
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsMonitor respiratory status; may cause bronchospasm; caution in breastfeeding



Deterrence/Prevention

  • Patients with underlying cardiopulmonary disease should receive annual influenza vaccinations.
  • In certain locations, such as in nursing homes, amantadine or rimantadine have been administered when an index case is found until the vaccine has had a chance to take effect. However, because of increasing resistance, their routine use has been discouraged by the CDC beginning in 2005 in favor of neuraminidase inhibitors.
  • Influenza vaccination of healthy patients may reduce absenteeism.

Complications

  • Fewer than 5% of patients with bronchitis develop pneumonia. Incidence of subsequent pneumonia, however, remains unaffected by the use of antibiotics.

Prognosis

  • For the vast majority of patients, the prognosis is excellent.

Patient Education



  1. National Center for Health Statistics. Current estimates from the national health interview survey: United States, 1994. Vital health statistics. 1995;10. [Medline].
  2. Black S. Epidemiology of pertussis. Pediatr Infect Dis J. Apr 1997;16(4 Suppl):S85-9. [Medline].
  3. Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest. Jan 2006;129(1 Suppl):95S-103S. [Medline].
  4. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. Sep 17 1997;278(11):901-4. [Medline].
  5. Franks P, Gleiner JA. The treatment of acute bronchitis with trimethoprim and sulfamethoxazole. J Fam Pract. Aug 1984;19(2):185-90. [Medline].
  6. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold. A randomized, double-blind, placebo-controlled study. Ann Intern Med. Jul 15 1996;125(2):81-8. [Medline].
  7. American Academy of Pediatrics. Committee on Drugs. Use of codeine- and dextromethorphan-containing cough remedies in children. American Academy of Pediatrics. Committee on Drugs. Pediatrics. Jun 1997;99(6):918-20. [Medline].
  8. Brickfield FX, Carter WH, Johnson RE. Erythromycin in the treatment of acute bronchitis in a community practice. J Fam Pract. Aug 1986;23(2):119-22. [Medline].
  9. Croughan-Minihane MS, Petitti DB, Rodnick JE. Clinical trial examining effectiveness of three cough syrups. J Am Board Fam Pract. Mar-Apr 1993;6(2):109-15. [Medline].
  10. Dunlay J, Reinhardt R, Roi LD. A placebo-controlled, double-blind trial of erythromycin in adults with acute bronchitis. J Fam Pract. Aug 1987;25(2):137-41. [Medline].
  11. Gonzales R, Bartlett JG, Besser RE. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Emerg Med. Jun 2001;37(6):720-7. [Medline].
  12. Gonzales R, Wilson A, Crane LA, Barrett PH. What's in a name? Public knowledge, attitudes, and experiences with antibiotic use for acute bronchitis. Am J Med. Jan 2000;108(1):83-5. [Medline].
  13. Huchon GJ, Gialdroni-Grassi G, Leophonte P, et al. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J. Aug 1996;9(8):1590-5. [Medline].
  14. Hueston WJ. A comparison of albuterol and erythromycin for the treatment of acute bronchitis. J Fam Pract. Nov 1991;33(5):476-80. [Medline].
  15. Hueston WJ. Albuterol delivered by metered-dose inhaler to treat acute bronchitis. J Fam Pract. Nov 1994;39(5):437-40. [Medline].
  16. King DE, Williams WC, Bishop L. Effectiveness of erythromycin in the treatment of acute bronchitis. J Fam Pract. Jun 1996;42(6):601-5. [Medline].
  17. Meza RA, Bridges-Webb C, Sayer GP, et al. The management of acute bronchitis in general practice: results from the Australian Morbidity and Treatment Survey, 1990-1991. Aust Fam Physician. Aug 1994;23(8):1550-3. [Medline].
  18. Molfino NA. Genetics of COPD. Chest. May 2004;125(5):1929-40. [Medline].
  19. Palmer DA, Bauchner H. Parents' and physicians' views on antibiotics. Pediatrics. Jun 1997;99(6):E6. [Medline].
  20. Siegel D, Sande MA. Patterns of antibiotic use in a busy metropolitan emergency room: analysis of efficacy and cost-appropriateness. West J Med. May 1983;138(5):737-41. [Medline].
  21. Smith NM, Bresee JS, Shay DK. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Jul 28 2006;55(RR-10):1-42. [Medline].
  22. Smucny J, Fahey T, Becker L, Glazier R. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2004;CD000245. [Medline].
  23. Snyder LD, Eisner MD. Obstructive lung disease among the urban homeless. Chest. May 2004;125(5):1719-25. [Medline].
  24. Stott NC, West RR. Randomised controlled trial of antibiotics in patients with cough and purulent sputum. Br Med J. Sep 4 1976;2(6035):556-9. [Medline].
  25. Taylor JA, Novack AH, Almquist JR. Efficacy of cough suppressants in children. J Pediatr. May 1993;122(5 Pt 1):799-802. [Medline].
  26. Williamson HA. A randomized, controlled trial of doxycycline in the treatment of acute bronchitis. J Fam Pract. Oct 1984;19(4):481-6. [Medline].

Bronchitis excerpt

Article Last Updated: Jul 5, 2008